Advance in studies on NGR peptide modified liposome and its anti-tumor performance.
- Author:
Yong WANG
1
;
Jun CHEN
;
Ai-Hu LIN
;
Yun FANG
Author Information
1. Pharmaceutical College of Nanjing University of Chinese Medicine, Nanjing 210046, China. wangxiaobei90@126.com
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Agents;
pharmacology;
CD13 Antigens;
administration & dosage;
pharmacology;
Humans;
Liposomes;
Oligopeptides;
administration & dosage;
pharmacology
- From:
China Journal of Chinese Materia Medica
2013;38(13):2041-2045
- CountryChina
- Language:Chinese
-
Abstract:
Aspargine-glycine-arginine (NGR)-containing peptides are targeted peptides which can be integrated with CD13 receptors on tumor vascular endothelial cells. NGR peptides are connected to liposomes to obtain NGR peptide-modified liposomes. By intravenous injection of these liposomes, NGR peptides can be combined with CD13 receptors on tumor vascular endothelial cells, position liposomes in tumor tissues, and concentrate drug in liposomes in tumor, so as to enhance the antitumor effect. The article starts with NGR peptides, summarizes definition of NGR, NGR peptide-modified liposomes, strengths and weaknesses of NGR peptide-modified liposomes in antitumor and the latest study orientation of NGR peptide-modified liposomes, and looks into the future of studies on NGR peptide-modified liposomes.
